中国药房2017，Vol.28Issue(5)：586-590,5.DOI:10.6039/j.issn.1001-0408.2017.05.03
塞来昔布在中国治疗骨关节炎的成本效果研究
Cost-effectiveness Study of Celecoxib for Osteoarthritis in China
摘要
Abstract
OBJECTIVE:To evaluate cost-effectiveness of celecoxib for osteoarthritis(OA)in China. METHODS:OA cost-ef-fectiveness analysis model developed by National Institute for Health and Clinical Excellence(NICE)was adopted using celecoxib, diclofenac+PPIs as control. Related risk Zof adverse event was from CONDOR trials.The effectiveness was measured by QALY. Costs and QALYs were discounted annually at 4.76%. RESULTS:Celecoxib had a cost of $3 591 and 8.826 QALYs while diclofe-nac+PPIs had a cost of $3 674 and 8.830 QALYs. The incremental costs and QALYs of celecoxib to diclofenac+PPIs were -$83 and -0.004 QALYs,respectively. The incremental cost-effectiveness ratio(ICER)for diclofenac+PPIs to celecoxib was$23 258/QALY. The results of single factor sensitivity analysis and probability sensitivity analysis showed that drug cost was driving factor of IC-ER,and the results of two therapy plans were similar. CONCLUSIONS:Celecoxib is a less costly alternative than diclofenac+PPIs. The difference in QALYs between celecoxib and diclofenac+PPIs is extremely small,so celecoxib is likely to be cost-effec-tive for OA patients.关键词
骨关节炎/塞来昔布/双氯芬酸/质子泵抑制剂/成本效果/药物经济学Key words
Osteoarthritis/Celecoxib/Diclofenac/PPI/Cost-effectiveness/Pharmacoeconomics分类
医药卫生引用本文复制引用
Bruce C.M. Wang,谢小平,Wesley Furnback,Ronald Caldwell..塞来昔布在中国治疗骨关节炎的成本效果研究[J].中国药房,2017,28(5):586-590,5.基金项目
辉瑞投资有限公司资助课题 （）
